Literature DB >> 29150352

Dysregulation of mRNA translation and energy metabolism in cancer.

Matthew Leibovitch1, Ivan Topisirovic2.   

Abstract

Dysregulated mRNA translation and aberrant energy metabolism are frequent in cancer. Considering that mRNA translation is an energy demanding process, cancer cells must produce sufficient ATP to meet energy demand of hyperactive translational machinery. In recent years, the mammalian/mechanistic target of rapamycin (mTOR) emerged as a central regulatory node which coordinates energy consumption by the translation apparatus and ATP production in mitochondria. Aberrant mTOR signaling underpins the vast majority of cancers whereby increased mTOR activity is thought to be a major determinant of both malignant translatomes and metabolomes. Nonetheless, the role of mTOR and other related signaling nodes (e.g. AMPK) in orchestrating protein synthesis and cancer energetics is only recently being unraveled. In this review, we discuss recent findings that provide insights into the molecular underpinnings of coordination of translational and metabolic programs of cancer cells, and potential strategies to translate these findings into clinical treatments.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cancer; Energy metabolism; mRNA translation; mTOR

Mesh:

Substances:

Year:  2017        PMID: 29150352      PMCID: PMC5993950          DOI: 10.1016/j.jbior.2017.11.001

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN: 2212-4926


  126 in total

1.  The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation.

Authors:  Jiangbin Ye; Monika Kumanova; Lori S Hart; Kelly Sloane; Haiyan Zhang; Diego N De Panis; Ekaterina Bobrovnikova-Marjon; J Alan Diehl; David Ron; Constantinos Koumenis
Journal:  EMBO J       Date:  2010-05-14       Impact factor: 11.598

Review 2.  Regulation and roles of elongation factor 2 kinase.

Authors:  Christopher G Proud
Journal:  Biochem Soc Trans       Date:  2015-06       Impact factor: 5.407

3.  A Transcript-Specific eIF3 Complex Mediates Global Translational Control of Energy Metabolism.

Authors:  Meera Shah; Dan Su; Judith S Scheliga; Tomáš Pluskal; Susanna Boronat; Khatereh Motamedchaboki; Alexandre Rosa Campos; Feng Qi; Elena Hidalgo; Mitsuhiro Yanagida; Dieter A Wolf
Journal:  Cell Rep       Date:  2016-07-28       Impact factor: 9.423

4.  Translational tolerance of mitochondrial genes to metabolic energy stress involves TISU and eIF1-eIF4GI cooperation in start codon selection.

Authors:  Hadar Sinvani; Ora Haimov; Yuri Svitkin; Nahum Sonenberg; Ana Tamarkin-Ben-Harush; Benoit Viollet; Rivka Dikstein
Journal:  Cell Metab       Date:  2015-03-03       Impact factor: 27.287

Review 5.  Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of rapamycin complex 2).

Authors:  Michael A Destefano; Estela Jacinto
Journal:  Biochem Soc Trans       Date:  2013-08       Impact factor: 5.407

Review 6.  The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway.

Authors:  Rachel L Wolfson; David M Sabatini
Journal:  Cell Metab       Date:  2017-08-01       Impact factor: 27.287

7.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.

Authors:  James Brugarolas; Kui Lei; Rebecca L Hurley; Brendan D Manning; Jan H Reiling; Ernst Hafen; Lee A Witters; Leif W Ellisen; William G Kaelin
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

8.  The mechanism for activation of GTP hydrolysis on the ribosome.

Authors:  Rebecca M Voorhees; T Martin Schmeing; Ann C Kelley; V Ramakrishnan
Journal:  Science       Date:  2010-11-05       Impact factor: 47.728

9.  nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs.

Authors:  Valentina Gandin; Laia Masvidal; Laura Hulea; Simon-Pierre Gravel; Marie Cargnello; Shannon McLaughlan; Yutian Cai; Preetika Balanathan; Masahiro Morita; Arjuna Rajakumar; Luc Furic; Michael Pollak; John A Porco; Julie St-Pierre; Jerry Pelletier; Ola Larsson; Ivan Topisirovic
Journal:  Genome Res       Date:  2016-03-16       Impact factor: 9.043

10.  Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.

Authors:  Étienne Audet-Walsh; Catherine R Dufour; Tracey Yee; Fatima Z Zouanat; Ming Yan; Georges Kalloghlian; Mathieu Vernier; Maxime Caron; Guillaume Bourque; Eleonora Scarlata; Lucie Hamel; Fadi Brimo; Armen G Aprikian; Jacques Lapointe; Simone Chevalier; Vincent Giguère
Journal:  Genes Dev       Date:  2017-07-19       Impact factor: 11.361

View more
  11 in total

1.  Overexpression of pyruvate dehydrogenase phosphatase 1 promotes the progression of pancreatic adenocarcinoma by regulating energy-related AMPK/mTOR signaling.

Authors:  Ye Li; Jia Shen; Chien-Shan Cheng; HuiFeng Gao; Jiangang Zhao; Lianyu Chen
Journal:  Cell Biosci       Date:  2020-08-06       Impact factor: 7.133

2.  Identification of a novel toxicophore in anti-cancer chemotherapeutics that targets mitochondrial respiratory complex I.

Authors:  Robert F Harvey; Kenneth R Pryde; Zoe A Stephenson; Sarah Mistry; Rachel E Hardy; Riccardo Serreli; Injae Chung; Timothy Eh Allen; Mark Stoneley; Marion MacFarlane; Peter M Fischer; Judy Hirst; Barrie Kellam; Anne E Willis
Journal:  Elife       Date:  2020-05-20       Impact factor: 8.140

Review 3.  Translating the Game: Ribosomes as Active Players.

Authors:  Piera Calamita; Guido Gatti; Annarita Miluzio; Alessandra Scagliola; Stefano Biffo
Journal:  Front Genet       Date:  2018-11-15       Impact factor: 4.599

4.  Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK.

Authors:  David Danielpour; Zhaofeng Gao; Patrick M Zmina; Eswar Shankar; Benjamin C Shultes; Raul Jobava; Scott M Welford; Maria Hatzoglou
Journal:  Sci Rep       Date:  2019-08-08       Impact factor: 4.996

Review 5.  mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer.

Authors:  Karen Griselda de la Cruz López; Mariel Esperanza Toledo Guzmán; Elizabeth Ortiz Sánchez; Alejandro García Carrancá
Journal:  Front Oncol       Date:  2019-12-13       Impact factor: 6.244

6.  Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.

Authors:  Katherine M Hannan; Jian Kang; Richard B Pearson; Eric P Kusnadi; Anna S Trigos; Carleen Cullinane; David L Goode; Ola Larsson; Jennifer R Devlin; Keefe T Chan; David P De Souza; Malcolm J McConville; Grant A McArthur; George Thomas; Elaine Sanij; Gretchen Poortinga; Ross D Hannan
Journal:  EMBO J       Date:  2020-09-18       Impact factor: 11.598

7.  Translational and post-translational control of human naïve versus primed pluripotency.

Authors:  Cheng Chen; Xiaobing Zhang; Yisha Wang; Xinyu Chen; Wenjie Chen; Songsong Dan; Shiqi She; Weiwei Hu; Jie Dai; Jianwen Hu; Qingyi Cao; Qianyu Liu; Yinghua Huang; Baoming Qin; Bo Kang; Ying-Jie Wang
Journal:  iScience       Date:  2021-12-17

8.  New insights into the cellular temporal response to proteostatic stress.

Authors:  Justin Rendleman; Zhe Cheng; Shuvadeep Maity; Nicolai Kastelic; Mathias Munschauer; Kristina Allgoewer; Guoshou Teo; Yun Bin Matteo Zhang; Amy Lei; Brian Parker; Markus Landthaler; Lindsay Freeberg; Scott Kuersten; Hyungwon Choi; Christine Vogel
Journal:  Elife       Date:  2018-10-12       Impact factor: 8.140

9.  Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver.

Authors:  Luise Spormann; Christiane Rennert; Erik Kolbe; Fritzi Ott; Carolin Lossius; Robert Lehmann; Rolf Gebhardt; Thomas Berg; Madlen Matz-Soja
Journal:  Cells       Date:  2020-07-31       Impact factor: 6.600

10.  Prediction of Poor Prognosis of HCC by Early Warning Model for Co-Expression of miRNA and mRNA Based on Bioinformatics Analysis.

Authors:  Zi-Jian Su; Chun-Cheng Lin; Jian-Hui Pan; Jian-Hua Zhang; Tao Han; Qunxiong Pan
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.